~~<i id='7AD963A685'><strike id='7AD963A685'><tt id='7AD963A685'><pre id='7AD963A685'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：Wikipedia 2025-10-02 12:38:57 Page View：46

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bristol Myers buys into radiopharmaceuticals with RayzeBio
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

focus

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

What STAT readers think about the FDA and patient advocacy

MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Abbott's new stent may help patients with peripheral artery disease

CardiovasculardoctorsareoptimisticaboutAbbott’snewbelow-kneestentthatdisappearsintothebloodvessel’sw